The invention provides a process for preparing 3-hydroxy-1-(3-(trifluoromethyl)-56-dihydro-[124]triazolo[43-a]pyrazin-7(8H)-yl)-4-(245-trifluorophenyl)butan-1-one (Formula I) into its racemic (R/S) form or any of its optically active (S) or (R) forms or enantiomeric excess mixture of any of the forms comprising: a) reacting 4-oxo-4-[3-(trifluoromethyl)-56-dihydro[124]triazolo[43-a]pyrazin-7(8H)-yl]-1-(245-trifluorophenyl)butan-2-one of formula (III) with a suitable oxidoreductase enzymes or its ...

The present invention relates to a method for treating reducing or preventing acne. In particular the present invention relates to methods for reducing the total number incidence and severity of acne lesions on the skin which includes both inflammatory and non-inflammatory lesions. Further the invention relates to reducing the incidence and severity of adverse events resulting from topical application of anti-acne agents resulting in improvement of skin tone. The method includes administering a ...

The invention discloses processes for the preparation of rivaroxaban and its pharmaceutically acceptable salts solvates and hydrates thereof. The invention also relates to novel intermediates for the preparation of rivaroxaban.

The invention relates to a process for preparing silodosin. The invention relates to the preparation of substantially pure silodosin. The invention also relates to silodosin solid particles wherein 90 volume-percent of the particles (D90) are less than 10 microns and a process for achieving the particle size (D90) less than 10 microns.

The present invention provides for press-coated tablets of prednisone comprising a core comprising prednisone and a coating around the core. The present invention particularly discloses thickness of the coating applied to core having a convex shape for chronotherapeutic use. The present invention also provides for a process for preparing a press-coated tablet of prednisone and a method for treating conditions or pathology the symptoms of which occur early in the morning.

The present invention relates to stable pharmaceutical compositions of (R)-lansoprazole or pharmaceutically acceptable salts thereof and process of preparing the same. The invention particularly provides pharmaceutical compositions of optically active (R)-isomer of lansoprazole with at least two functional coating layers.

The present invention discloses an extended release pharmaceutical composition of pramipexole or salts thereof comprising at least 40% w/w of hydrogenated castor oil and one or more pharmaceutically acceptable excipients.

The present invention relates to delayed release oral disintegrating pharmaceutical compositions of lansoprazole or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of such compositions.

Disclosed are compounds of general formula (I) their stereoisomers regioisomers tautomeric forms and novel intermediates involved in their synthesis their pharmaceutically acceptable salts. These compounds are suitable as Poly (ADP-ribose) polymerase-1 inhibitors (PARP-1 inhibitors).

The present invention discloses a stable crystalline Form-I of linesolid process for preparation thereof.